ASND
Ascendis A/SFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Successful clinical readouts, clear regulatory paths, or a strategic partnership could drive material re-rating; commercial execution on approved programs would further de-risk the story.
Posture
Defensive
Lead driver
Value
What changed
1 setup hits (3d) with net bullish as of 2026-07-16.
What can break
Clinical trial failure or negative readout
Momentum
68
Value
48
Sentiment
0
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $28.16 · Bull $46.08 · Bear $12.80
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-16 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2025-10-02 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Bullish
Target $300.00
Why
Momentum68 · Δ7d -3.9
Value48 · Δ7d -0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
68
26% active weight
Current posture
7d trendFlat
Δ7d
-3.9
Δ21d
+17.6
Value
48
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.0
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 68.1 / Value 48.4 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-16
Fundamentals (TTM)
As of 2026-07-16
Market Cap
$16.21B
Beta
0.43
Shares Out
62.11M
P/E (TTM) · Derived
-61.4
P/S (TTM)
17.35
P/FCF (TTM) · Derived
312.54
Rev YoY
+171.5%
EPS YoY
-819.4%
Gross Margin
+87.4%
Op Margin
-22.5%
Net Debt
$300.36M
Current Ratio
1.00
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology